Magnetic resonance spectroscopy of living tissues.

The comprehensive work of both clinical and basic science colleagues has demonstrated a clear proof of concept for "in vitro discovered- in vivo validated" biomarkers in translational metabolic profiling research using magnetic resonance techniques. Major tissue metabolites (initially discovered by high-resolution in vitro techniques on cancer specimens) can be translated into in vivo protocols based on noninvasive magnetic resonance spectroscopy (MRS). Using (1)H- and (31)P-MRS on living animals or patients, a decrease in citrate and polyamines in prostate cancer, an increase of cholines in breast cancer, as well as a decreased NAA and an increased lactate in gliomas during cancer progression can be assessed noninvasively. MRS can be used to follow up conventional cytotoxic as well as targeted anticancer therapies, which has been extensively done in animal models of cancer. This review focuses on applications and protocol development for in vivo (1)H- and (31)P-MRS on small animal models as well as on larger animals in cancer research, diagnosis, and treatment.

[1]  B. Tomanek,et al.  Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T , 2005, European Radiology.

[2]  J. Pauly,et al.  Dualband spectral‐spatial RF pulses for prostate MR spectroscopic imaging , 2001, Magnetic resonance in medicine.

[3]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[4]  S. Nelson.  Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors , 2001, Magnetic resonance in medicine.

[5]  H. Thaler,et al.  Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. , 2003, Cancer research.

[6]  R. Kauppinen,et al.  Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. , 2003, Cancer research.

[7]  R. Gillies,et al.  In vivo magnetic resonance spectroscopy in cancer. , 2005, Annual review of biomedical engineering.

[8]  Michael Garwood,et al.  Imaging in breast cancer: Magnetic resonance spectroscopy , 2005, Breast Cancer Research.

[9]  N. Serkova,et al.  Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. , 2006, Pharmacogenomics.

[10]  H. Hricak,et al.  Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. , 2004, Clinical prostate cancer.

[11]  J. Griffiths,et al.  Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy , 2005, Clinical Cancer Research.

[12]  T. Brown,et al.  Methodological standardization for a multi‐institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies , 2004, NMR in biomedicine.

[13]  R. Gillies,et al.  Applications of magnetic resonance in model systems: cancer therapeutics. , 2000, Neoplasia.

[14]  T. Reese,et al.  In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives , 1999, NMR in biomedicine.

[15]  R. DeLaPaz,et al.  Multisection 1H Magnetic Resonance Spectroscopic Imaging Assessment of Glioma Response to Chemotherapy , 2005, Journal of Neuro-Oncology.

[16]  C. Mountford,et al.  Cancer pathology in the year 2000. , 1997, Biophysical chemistry.

[17]  R. Gillies,et al.  Applications of magnetic resonance in model systems: tumor biology and physiology. , 2000, Neoplasia.

[18]  John R Griffiths,et al.  Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. , 2002, Cancer research.

[19]  J. Griffiths,et al.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. , 2006, Cancer research.